TY - JOUR
T1 - Baseline data of parasite clearance in patients with falciparum malaria treated with an artemisinin derivative
T2 - An individual patient data meta-analysis
AU - WWARN Parasite Clearance Study Group
AU - Abdulla, Salim
AU - Ashley, Elizabeth A.
AU - Bassat, Quique
AU - Bethell, Delia
AU - Björkman, Anders
AU - Borrmann, Steffen
AU - D’Alessandro, Umberto
AU - Dahal, Prabin
AU - Day, Nicholas P.
AU - Diakite, Mahamadou
AU - Djimde, Abdoulaye A.
AU - Dondorp, Arjen M.
AU - Duong, Socheat
AU - Edstein, Michael D.
AU - Fairhurst, Rick M.
AU - Abul Faiz, M.
AU - Falade, Catherine
AU - Flegg, Jennifer A.
AU - Fogg, Carole
AU - Gonzalez, Raquel
AU - Greenwood, Brian
AU - Guérin, Philippe J.
AU - Guthmann, Jean Paul
AU - Hamed, Kamal
AU - Tinh Hien, Tran
AU - Htut, Ye
AU - Juma, Elizabeth
AU - Lim, Pharath
AU - Mårtensson, Andreas
AU - Mayxay, Mayfong
AU - Mokuolu, Olugbenga A.
AU - Moreira, Clarissa
AU - Newton, Paul
AU - Noedl, Harald
AU - Nosten, Francois
AU - Ogutu, Bernhards R.
AU - Onyamboko, Marie A.
AU - Owusu-Agyei, Seth
AU - Pyae Phyo, Aung
AU - Premji, Zul
AU - Price, Ric N.
AU - Pukrittayakamee, Sasithon
AU - Ramharter, Michael
AU - Sagara, Issaka
AU - Se, Youry
AU - Suon, Seila
AU - Stepniewska, Kasia
AU - Ward, Stephen A.
AU - White, Nicholas J.
AU - Winstanley, Peter A.
N1 - Publisher Copyright:
© 2015 WWARN Parasite Clearance Study Group.
PY - 2015/9/22
Y1 - 2015/9/22
N2 - Background: Artemisinin resistance in Plasmodium falciparum manifests as slow parasite clearance but this measure is also influenced by host immunity, initial parasite biomass and partner drug efficacy. This study collated data from clinical trials of artemisinin derivatives in falciparum malaria with frequent parasite counts to provide reference parasite clearance estimates stratified by location, treatment and time, to examine host factors affecting parasite clearance, and to assess the relationships between parasite clearance and risk of recrudescence during follow-up. Methods: Data from 24 studies, conducted from 1996 to 2013, with frequent parasite counts were pooled. Parasite clearance half-life (PC1/2) was estimated using the WWARN Parasite Clearance Estimator. Random effects regression models accounting for study and site heterogeneity were used to explore factors affecting PC1/2 and risk of recrudescence within areas with reported delayed parasite clearance (western Cambodia, western Thailand after 2000, southern Vietnam, southern Myanmar) and in all other areas where parasite populations are artemisinin sensitive. Results: PC1/2 was estimated in 6975 patients, 3288 of whom also had treatment outcomes evaluate d during 28-63 days follow-up, with 93 (2.8 %) PCR-confirmed recrudescences. In areas with artemisinin-sensitive parasites, the median PC1/2 following three-day artesunate treatment (4 mg/kg/day) ranged from 1.8 to 3.0 h and the proportion of patients with PC1/2 >5 h from 0 to 10 %. Artesunate doses of 4 mg/kg/day decreased PC1/2 by 8.1 % (95 % CI 3.2-12.6) compared to 2 mg/kg/day, except in populations with delayed parasite clearance. PC1/2 was longer in children and in patients with fever or anaemia at enrolment. Long PC1/2 (HR = 2.91, 95 % CI 1.95-4.34 for twofold increase, p < 0.001) and high initial parasitaemia (HR = 2.23, 95 % CI 1.44-3.45 for tenfold increase, p < 0.001) were associated independently with an increased risk of recrudescence. In western Cambodia, the region with the highest prevalence of artemisinin resistance, there was no evidence for increasing PC1/2 since 2007. Conclusions: Several factors affect PC1/2. As substantial heterogeneity in parasite clearance exists between locations, early detection of artemisinin resistance requires reference PC1/2 data. Studies with frequent parasite count measurements to characterize PC1/2 should be encouraged. In western Cambodia, where PC1/2 values are longest, there is no evidence for recent emergence of higher levels of artemisinin resistance.
AB - Background: Artemisinin resistance in Plasmodium falciparum manifests as slow parasite clearance but this measure is also influenced by host immunity, initial parasite biomass and partner drug efficacy. This study collated data from clinical trials of artemisinin derivatives in falciparum malaria with frequent parasite counts to provide reference parasite clearance estimates stratified by location, treatment and time, to examine host factors affecting parasite clearance, and to assess the relationships between parasite clearance and risk of recrudescence during follow-up. Methods: Data from 24 studies, conducted from 1996 to 2013, with frequent parasite counts were pooled. Parasite clearance half-life (PC1/2) was estimated using the WWARN Parasite Clearance Estimator. Random effects regression models accounting for study and site heterogeneity were used to explore factors affecting PC1/2 and risk of recrudescence within areas with reported delayed parasite clearance (western Cambodia, western Thailand after 2000, southern Vietnam, southern Myanmar) and in all other areas where parasite populations are artemisinin sensitive. Results: PC1/2 was estimated in 6975 patients, 3288 of whom also had treatment outcomes evaluate d during 28-63 days follow-up, with 93 (2.8 %) PCR-confirmed recrudescences. In areas with artemisinin-sensitive parasites, the median PC1/2 following three-day artesunate treatment (4 mg/kg/day) ranged from 1.8 to 3.0 h and the proportion of patients with PC1/2 >5 h from 0 to 10 %. Artesunate doses of 4 mg/kg/day decreased PC1/2 by 8.1 % (95 % CI 3.2-12.6) compared to 2 mg/kg/day, except in populations with delayed parasite clearance. PC1/2 was longer in children and in patients with fever or anaemia at enrolment. Long PC1/2 (HR = 2.91, 95 % CI 1.95-4.34 for twofold increase, p < 0.001) and high initial parasitaemia (HR = 2.23, 95 % CI 1.44-3.45 for tenfold increase, p < 0.001) were associated independently with an increased risk of recrudescence. In western Cambodia, the region with the highest prevalence of artemisinin resistance, there was no evidence for increasing PC1/2 since 2007. Conclusions: Several factors affect PC1/2. As substantial heterogeneity in parasite clearance exists between locations, early detection of artemisinin resistance requires reference PC1/2 data. Studies with frequent parasite count measurements to characterize PC1/2 should be encouraged. In western Cambodia, where PC1/2 values are longest, there is no evidence for recent emergence of higher levels of artemisinin resistance.
KW - Artemisinin resistance
KW - Drug resistance
KW - Malaria
KW - Parasite clearance
KW - Plasmodium falciparum
UR - http://www.scopus.com/inward/record.url?scp=84942511604&partnerID=8YFLogxK
U2 - 10.1186/s12936-015-0874-1
DO - 10.1186/s12936-015-0874-1
M3 - Article
C2 - 26390866
AN - SCOPUS:84942511604
SN - 1475-2875
VL - 14
JO - Malaria Journal
JF - Malaria Journal
IS - 1
M1 - 359
ER -